Skip to content

AARD AARD Investing Cash Flow

Investing Cash Flow at other companies

AbbVie logo
AbbVieABBV
-$574M+21.9%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$135.23M-980%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$57.05M+130%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$52K+61.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$54.19M-14.3%
Arvinas logo
ArvinasARVN
$13.7M-80.3%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's investing cash flow?
AARD (AARD) reported investing cash flow of $34.25M in Q1 2026.
How has AARD's investing cash flow changed year-over-year?
AARD's investing cash flow increased by 130.4% year-over-year, from -$112.62M to $34.25M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.